ERBB2 and breast carcinoma: Displaying promise in pre-clinical studies, lapatinib was shown to inhibit the growth of trastuzumab-resistant cancer cells[31] and was shown to have additive effects with HER2-targeted antibodies[32,33], offering hope for the treatment of breast cancer patients who previously relapsed on trastuzumab-based therapies.